![](/assets/images/TRDizinlogo.png)
Efficacy of Colistin Therapy in Patients with Hematological Malignancies: What if There is Colistin Resistance?
Yıl: 2023 Cilt: 29 Sayı: 1 Sayfa Aralığı: 17 - 22 Metin Dili: İngilizce DOI: 10.58600/eurjther-340 İndeks Tarihi: 27-04-2023
Efficacy of Colistin Therapy in Patients with Hematological Malignancies: What if There is Colistin Resistance?
Öz: Objective: The objective of this study was to evaluate the clinical efficacy and appropriateness of colistin therapy in patients with hematological malignancies. Methods: Age, gender, type of hematologic malignancy, and potential carbapenem-resistant microorganism risk factors were all noted in this retrospective study. In empirical and agent-specific treatment groups, differences in demographic features, risk factors, treatment responses, and side effects were compared. Results: Sixty-three patients were included, 54% were male, and the median age was 49. In the last three months, the hospital ization rate history was 68%, and four patients had a hospitalization history in the ICU. Carbapenem-resistant K. pneumoniae col onization was present in 22 patients (35%). Gram-negative microorganisms were isolated in 34 patients (54%). The carbapenem, quinolone, and colistin resistance rates were 82%, 76%, and 4% respectively. Clinical and microbiological response rates were 60% and 69%. 7 and 28-day mortality rates were 17% and 35%. There was no significant difference in demographic data and comorbid ities in empirical (n=48) and agent-specific (n=15) treatment groups. The rate of carbapenem and glycopeptide treatments before colistin was higher in the empirical treatment group (p = 0.004; p = 0.001). The rate of starting combined antibiotics was higher in the empirical treatment group (p = 0.016). Two of the patients developed renal failure in the first week after treatment. Conclusion: The use of empirical colistin may be unavoidable given the risk considerations. Shortly, colistin-resistant strains may also be a factor affecting treatment success negatively.
Anahtar Kelime: Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
- 1- Averbuch D, Horwitz E, Strahilevitz J, Stepensky P, Goldschmidt N, Gatt ME, et al. Colistin is relatively safe in hematological malignancies and hematopoietic stem cell transplantation patients.Infection. 2013;41(5):991-7.
- 2- Wang X, Zhang L, Sun A, Yang X, Sang W, Jiang Y, et al. Acinetobacter baumannii bacteraemia in patients with haematological malignancy:a multicentre retrospective study fromthe Infection Working Party of Jiangsu Society of Hematology. Eur J ClinMicrobiol Infect Dis. 2017;36(7):1073-1081.
- 3- Pohlen M, Marx J, Mellmann A, Becker K, Mesters RM, Mikesch JH, et al. Ciprofloxacin versus colistin prophylaxis during neutropenia in acute myeloid leukemia: two parallel patient cohorts treated in a single center. Haematologica. 2016 Oct;101(10):1208-1215.
- 4- Kaskatepe B, Yildiz SS, Mumcuoglu I, Ozet G, Altuntas EG. RS sample: Can be guide for empirical treatment of haematological malignancy patients? MicrobPathog. 2018;125:164-167.
- 5- Kokkayil P, Agarwal R, Mohapatra S, Bakshi S, Das B, Sood S. Bacterial profile and antibiogram of blood stream infections in febrile neutropenic patients with haematological malignancies. J Infect Dev Ctries. 2018;12(6):442-447.
- 6- Zavascki AP, Girardello R, Magagnin CM, Antochevis LC, Maciel RA, Palmeiro JK, et al. Emergence of polymyxin B resistance in a polymyxin B-susceptible KPC-producing Klebsiella pneumoniae causing bloodstream infection in a neutropenic patient during polymyxin B therapy. DiagnMicrobiol Infect Dis. 2018;90(2):134-138.
- 7- Pormohammad A, Mehdinejadiani K, Gholizadeh P, Nasiri MJ, Mohtavinejad N, Dadashi M, et al. Global prevalence of colistin resistance in clinical isolates of Acinetobacter baumannii: A systematic review and meta-analysis. Microb Pathog. 2020;139:103887.
- 8- Zafer MM, El-Mahallawy HA, Abdulhak A, Amin MA, Al-Ag-amy MH, Radwan HH. Emergence of colistin resistance in multidrug-resistant Klebsiella pneumoniae and Escherichia coli strains isolated from cancer patients. Ann Clin Microbiol Antimicrob. 2019 Dec 12;18(1):40. doi: 10.1186/s12941-019- 0339-4.
- 9- Ghosh S, Chakraborty M, Samanta S, Sinha N, Saha S, Chattopadhyay A, et al. of blood stream infections, antibiograms and clinical outcomes in haematological patients with febrile neutropenia: data from a tertiary care haematology institute in India. Ann Hematol. 2020 Nov 2. doi: 10.1007/s00277-020-04324-8. Epub ahead of print.
- 10- Liu P, Li X, Luo M, Xu X, Su K, Chen S, et al. Rish factors for Carbapenem-Resistant Klebsiella pneumoniae Infection: A Meta-Analysis. Microb Drug Resist. 2018;24(2):190-198. doi: 10.1089/mdr.2017.0061. Epub 2017 Jul 27
- 11- Liu J, Wang H, Huang Z, Tao X, Li J, Hu Y, et al. Risk factors and outcomes for carbapenem-resistant Klebsiella pneumoniae bacteremia in onco-hematological patients. J Infect Dev Ctries. 2019;13(5):357-364. doi: 10.3855/jidc.11189.
- 12- Dickstein Y, Lellouche J, Ben Dalak Amar M, Schwartz D, Nutman A, Daitch V et al; AIDA Study Group. Treatment Outcomes of Colistin- and Carbapenem-resistant Acinetobacter baumannii Infections: An Exploratory Subgroup Analysis of a Randomized Clinical Trial. Clin Infect Dis. 2019;69(5):769-776. doi: 10.1093/cid/ciy988
- 13- Papadimitriou-Olivgeris M, Fligou F, Spiliopoulou A, Koutsileou K, Kolonitsiou F, Spyropoulou A, et al. Risk factors and predictors of carbapenem-resistant Pseudomonas aeruginosa and Acinetobacter baumannii mortality in critically ill bacteraemic patients over a 6-year period (2010-15): antibiotics do matter. J Med Microbiol. 2017;66(8):1092-1101. doi: 10.1099/jmm.0.000538
- 14- Zarkotou O, Pournaras S, Voulgari E, Chrysos G, Prekates A, Voutsinas D, et al. Risk factors and outcomes associated with acquisition of colistin-resistant KPC-producing Klebsiella pneumoniae: a matched case-control study. J Clin Microbiol. 2010;48(6):2271-4. doi: 10.1128/JCM.02301-09. Epub 2010 Apr 7.
- 15- Metan G, Demiraslan H, Kaynar LG, Zararsız G, Alp E, Eser B. Factors influencing the early mortality in haematological malignancy patients with nosocomial Gram negative bacilli bacteraemia: a retrospective analysis of 154 cases. Braz J Infect Dis. 2013;17(2):143-9. doi: 10.1016/j.bjid.2012.09.010.
- 16- Metan G, Pala Ç, Kaynar L, Cevahir F, Alp E. A nightmare for haematology clinics: extensively drug-resistant (XDR) Acinetobacter baumannnii. Infez Med. 2014;22(4):277-82.
- 17- Sertcelik A, Baran I, Akinci E, Mumcuoglu I, Bodur H. Synergistic Activities of Colistin Combinations with Meropenem, Sulbactam, Minocycline, Disodium Fosfomycin, or Vancomycin Against Different Clones of Carbapenem-Resistant Acinetobacter baumannii Strains. Microb Drug Resist. 2020;26(5):429-433. doi: 10.1089/mdr.2019.0088.
- 18- Bae S, Kim MC, Park SJ, Kim HS, Sung H, Kim MN, et al. In Vitro Synergistic Activity of Antimicrobial Agents in Combination against Clinical Isolates of Colistin-Resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2016;60(11):6774-6779. doi: 10.1128/AAC.00839-16.
- 19- Durakovic N, Radojcic V, Boban A, Mrsic M, Sertic D, Serventi-Seiwerth R, et al. Efficacy and safety of colistin in the treatment of infections caused by multidrug-resistant Pseudomonas aeruginosa in patients with hematologic malignancy: a matched pair analysis. Intern Med. 2011;50(9):1009-13. doi: 10.2169/internalmedicine.50.4270. Epub 2011 May 1
APA | TÜRE Z, Kalin Unuvar G, kahveci h, Keklik M, Ulu Kılıç A (2023). Efficacy of Colistin Therapy in Patients with Hematological Malignancies: What if There is Colistin Resistance?. , 17 - 22. 10.58600/eurjther-340 |
Chicago | TÜRE Zeynep Ture,Kalin Unuvar Gamze,kahveci hüseyin nadir,Keklik Muzaffer,Ulu Kılıç Aysegul Efficacy of Colistin Therapy in Patients with Hematological Malignancies: What if There is Colistin Resistance?. (2023): 17 - 22. 10.58600/eurjther-340 |
MLA | TÜRE Zeynep Ture,Kalin Unuvar Gamze,kahveci hüseyin nadir,Keklik Muzaffer,Ulu Kılıç Aysegul Efficacy of Colistin Therapy in Patients with Hematological Malignancies: What if There is Colistin Resistance?. , 2023, ss.17 - 22. 10.58600/eurjther-340 |
AMA | TÜRE Z,Kalin Unuvar G,kahveci h,Keklik M,Ulu Kılıç A Efficacy of Colistin Therapy in Patients with Hematological Malignancies: What if There is Colistin Resistance?. . 2023; 17 - 22. 10.58600/eurjther-340 |
Vancouver | TÜRE Z,Kalin Unuvar G,kahveci h,Keklik M,Ulu Kılıç A Efficacy of Colistin Therapy in Patients with Hematological Malignancies: What if There is Colistin Resistance?. . 2023; 17 - 22. 10.58600/eurjther-340 |
IEEE | TÜRE Z,Kalin Unuvar G,kahveci h,Keklik M,Ulu Kılıç A "Efficacy of Colistin Therapy in Patients with Hematological Malignancies: What if There is Colistin Resistance?." , ss.17 - 22, 2023. 10.58600/eurjther-340 |
ISNAD | TÜRE, Zeynep Ture vd. "Efficacy of Colistin Therapy in Patients with Hematological Malignancies: What if There is Colistin Resistance?". (2023), 17-22. https://doi.org/10.58600/eurjther-340 |
APA | TÜRE Z, Kalin Unuvar G, kahveci h, Keklik M, Ulu Kılıç A (2023). Efficacy of Colistin Therapy in Patients with Hematological Malignancies: What if There is Colistin Resistance?. European Journal of Therapeutics, 29(1), 17 - 22. 10.58600/eurjther-340 |
Chicago | TÜRE Zeynep Ture,Kalin Unuvar Gamze,kahveci hüseyin nadir,Keklik Muzaffer,Ulu Kılıç Aysegul Efficacy of Colistin Therapy in Patients with Hematological Malignancies: What if There is Colistin Resistance?. European Journal of Therapeutics 29, no.1 (2023): 17 - 22. 10.58600/eurjther-340 |
MLA | TÜRE Zeynep Ture,Kalin Unuvar Gamze,kahveci hüseyin nadir,Keklik Muzaffer,Ulu Kılıç Aysegul Efficacy of Colistin Therapy in Patients with Hematological Malignancies: What if There is Colistin Resistance?. European Journal of Therapeutics, vol.29, no.1, 2023, ss.17 - 22. 10.58600/eurjther-340 |
AMA | TÜRE Z,Kalin Unuvar G,kahveci h,Keklik M,Ulu Kılıç A Efficacy of Colistin Therapy in Patients with Hematological Malignancies: What if There is Colistin Resistance?. European Journal of Therapeutics. 2023; 29(1): 17 - 22. 10.58600/eurjther-340 |
Vancouver | TÜRE Z,Kalin Unuvar G,kahveci h,Keklik M,Ulu Kılıç A Efficacy of Colistin Therapy in Patients with Hematological Malignancies: What if There is Colistin Resistance?. European Journal of Therapeutics. 2023; 29(1): 17 - 22. 10.58600/eurjther-340 |
IEEE | TÜRE Z,Kalin Unuvar G,kahveci h,Keklik M,Ulu Kılıç A "Efficacy of Colistin Therapy in Patients with Hematological Malignancies: What if There is Colistin Resistance?." European Journal of Therapeutics, 29, ss.17 - 22, 2023. 10.58600/eurjther-340 |
ISNAD | TÜRE, Zeynep Ture vd. "Efficacy of Colistin Therapy in Patients with Hematological Malignancies: What if There is Colistin Resistance?". European Journal of Therapeutics 29/1 (2023), 17-22. https://doi.org/10.58600/eurjther-340 |